A genetic model showed that altered baseline neurobiology changed one measured response to diazepam.
Mice lacking Slc18b1 had reduced brain polyamine content, memory deficits, and changes in expression of genes related to plasticity and neurotransmitter signaling. They also showed a smaller diazepam-related reduction in locomotion, described as partial resistance in that behavioral measure.
The result does not establish resistance to every diazepam effect. Locomotor suppression, memory, anticonvulsant action, and respiratory effects are separate endpoints.
The animals had a defined gene deletion rather than a documented history of repeated benzodiazepine use. The experiment therefore cannot be used as proof of clinical tolerance or dependence. The proposed signaling explanation remains tied to the model.
For forensic communication, specify which drug response was measured and how the groups differed before treatment. The paper illustrates biological variability in an animal system, not a test for explaining an individual’s apparent resistance to sedation.
Original analysis of the supplied journal article, identified as PMC6927659.